Save Money with Carterra & Excedr
Lease a Carterra® instrument and receive up to 3 months off your lease. Average savings are $85,000+.
High Throughput Antibody Screening & Characterization
Carterra offers fully integrated Surface Plasmon Resonance (SPR) platforms that transform your label-free characterization workflow. These label-free biosensors for characterization of large and small molecules come in different packages, all tailored to meet your screening and characterization needs.
Explore a range of instruments within the LSA platform
- LSA: A high-throughput SPR platform that delivers up to 100x more data with minimal sample use, lower costs, and faster results.
- LSA XT: An enhanced LSA system with greater sensitivity, enabling deeper insights and broader drug discovery applications
- ULTRA: Carterra’s most advanced HT-SPR platform, designed for high-sensitivity screening of small molecules, fragments, and large arrays.
Every instrument includes:
- Sensor Chips & Solutions
- Industry-leading Kinetics Software
- Industry-leading Epitope Software
- AI, ML and In Silico Tools
Through Excedr's partnership with Carterra, customers can lease a Carterra® instrument and receive up to 3 months off their lease—unlocking average savings of $85,000+ while preserving capital.
LSA Platform Brochure
About Carterra
Carterra® is a leading provider of innovative technologies designed to accelerate the discovery of novel large and small molecule therapeutic candidates. With 100x the data, in 10% of the time, using just 1% of the sample, Carterra’s LSA platform accelerates drug discovery like no other.
“At Twist, we have developed a disruptive DNA synthesis platform to industrialize the engineering of biology. To match our capacity in generating antibody libraries, we use the Carterra LSA for screening and characterization.
Its high throughput capabilities match our highly automated antibody production workflow and shift analytics upstream to the very start of our antibody production. We routinely generate binding kinetics on hundreds of clones in parallel, directly from crude antibody or purified samples using minimal sample.
Additionally, epitope binning studies on large panels of antibodies are now possible early in a program, allowing us to assess the epitope coverage of our libraries quickly and identify clones with uniquely desirable binding properties.”
Aaron Sato
Chief Scientific Officer, Biopharma at Twist
Lease & Save on Your First 3 Months
As an Excedr client, you receive 3 months off your first lease when you lease an instrument from Carterra. Get in touch to begin the process and start saving.